Thursday, August 20, 2026

Why Kim Jong Un Chose Housing Over Missile Tests Amid U.S. Drills

North Korea refrains from military action during U.S.-South Korea exercises, focusing on economic priorities and diplomatic maneuvers.

Olympic Medalists Take Selfies on the Podium for the First Time!

For the first time in history, athletes at the Paris Olympics are capturing their triumphant moments on the podium with selfies.

Man Fined After Assaulting Wife and Threatening Her with Weapon Over Divorce Dispute

A man was fined for assaulting his wife during a divorce dispute, threatening her with a weapon, and causing property damage.

Tag: Hanmi Pharmaceutical

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Why Hanmi Pharmaceutical’s Pyeongtaek Manufacturing Center Achieved Top Safety Rating Again in 2026?

Hanmi Pharmaceutical's Pyeongtaek manufacturing center received the highest P grade in a safety management assessment by the Ministry of Employment and Labor.

Belvarafenib: The Promising New Targeted Cancer Drug for NRAS Mutant Melanoma

Hanmi Pharmaceutical presents Belvarafenib's phase 2 trial for NRAS mutant melanoma at KCA 2026, targeting unmet medical needs.

Hanmi Pharmaceutical completes acquisition of Aptose Biosciences

Hanmi Pharmaceutical has acquired Aptose Biosciences for $46.7 million, regaining rights to the cancer drug tuspetinib.

A Record Year in China Is Giving Hanmi Pharmaceutical More Firepower for What’s Next

Hanmi Pharmaceutical's Chinese subsidiary surpassed $290M in sales, contributing significantly to the group's growth and future investments.

Hanmi Pharmaceutical’s Leadership Shake-Up: What Does New CEO Hwang Sang-yeon Mean for the Future?

Hanmi Pharmaceutical Group's management dispute appears to be resolved, marking its first external leadership in 53 years.

Hanmi Posts Record $1.16B Sales and $193M Operating Profit: What’s Driving the 2025 Surge

Hanmi Pharmaceutical reports record sales of $1.16 billion in January 2025, with significant growth in profits and new product launches.

FDA Grants Breakthrough Therapy Designation to Hanmi’s Epheglucagon: What This Means for Rare Disease Treatment

Hanmi Pharmaceutical's efpegerglucagon receives FDA Breakthrough Therapy designation for treating rare Congenital Hyperinsulinism, with Phase 2 results due soon.

How MiniRin and Nokdernah Are Revolutionizing Nocturia Care for Seniors: A Comprehensive Guide

Hanmi Pharmaceutical and Ferring Korea partner to distribute Minirin and Nocdurna for nocturia treatment, enhancing patient access.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.